Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Report 2026

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Overview

• Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy market size has reached to $2.42 billion in 2025 • Expected to grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.2% • Growth Driver: Surge In Cancer Incidence Driving The Growth Of The Market Due To Increasing Global Aging And Unhealthy Lifestyles • Market Trend: Novel Alloimmune Defense Receptor Technology Enables Safer Chimeric Antigen Receptor-Natural Killer Therapies Without Intense Chemotherapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market?

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy refers to a cutting-edge immunotherapy that involves genetically modifying natural killer (NK) cells with chimeric antigen receptors (CARs) to recognize and eliminate cancer cells more effectively. It is widely utilized for the treatment of hematologic malignancies, solid tumors, and certain viral infections and offers distinct advantages such as lower risk of cytokine release syndrome (CRS), reduced graft-versus-host disease (GvHD) potential, and suitability for allogeneic (off-the-shelf) applications. The main types of chimeric antigen receptor-natural killer (CAR-NK) cell therapy include cytokine therapy, adoptive natural killer (NK) cell therapy, genetically engineered natural killer cell therapy, and others. Cytokine therapy is a treatment that uses signaling proteins (cytokines) such as interferons or interleukins to modulate the immune system, either to stimulate anti-tumor responses or suppress harmful inflammation in autoimmune diseases. The different cell sources are peripheral blood-derived natural killer cells, cord blood-derived natural killer cells, induced pluripotent stem cell (iPSC)-derived natural killer cells, and natural killer cell lines. The various applications involved are solid tumors, hematological malignancies, and others, and they are used by several end users such as hospitals, cancer research institutes, and biotechnology and pharmaceutical companies.

What Is The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Growth Forecast?

The chimeric antigen receptor-natural killer (car-nk) cell therapy market size is expected to see strong growth in the next few years. It will grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to development of genetically engineered car-nk cells, expansion of off-the-shelf therapies, rising adoption of cytokine and t cell receptor modified nk cells, increasing funding for clinical trials, integration of ai and big data in therapy optimization. Major trends in the forecast period include growth in allogeneic (off-the-shelf) car-nk cell therapies, expansion of hematological malignancy and solid tumor applications, integration of gene editing and cytokine gene modification techniques, increasing adoption of combination and immune checkpoint therapies, rising investment in clinical trials and oncology research programs.

What Is The Driver Of The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market?

The rising incidence of cancer worldwide is expected to propel the growth of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells that can invade and damage body tissues. The rising incidence of cancer is due to factors such as aging populations and unhealthy lifestyles, as older age increases mutation accumulation over time and poor habits such as smoking, poor diet, and inactivity raise cancer risk. Chimeric antigen receptor-natural killer (CAR-NK) cell therapy supports cancer treatment by engineering natural killer cells to precisely identify and destroy cancer cells, strengthening the immune system’s targeted attack on tumors. For instance, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, estimated the 20 million new cases of cancer in 2022 are expected to rise by 77% to over 35 million cases in 2050. Therefore, the rising incidence of cancer worldwide is driving the growth of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy industry.

Key Players In The Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

Major companies operating in the chimeric antigen receptor-natural killer (car-nk) cell therapy market are Artiva Biotherapeutics Inc., Nkarta Inc., Fate Therapeutics Inc., Acepodia Inc., Cartherics Inc., Century Therapeutics Inc., Catamaran Bio Inc., Glycostem Therapeutics Ltd., ImmuneBridge Co. Ltd., ONK Therapeutics Inc., Senti Biosciences Inc., Wugen Therapeutics Inc., Chimeric Therapeutics Limited, Nuwacell Biotechnologies Co. Ltd., Nkarta Therapeutics Inc., GICELL Co. Ltd.

Global Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Trends and Insights

Major companies operating in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market are focusing on developing advanced solutions, such as conditioning chemotherapy-free treatment, to develop safer and more effective off-the-shelf cellular therapies. Conditioning chemotherapy-free treatment is a therapy approach that eliminates the need for intensive pre-treatment chemotherapy to suppress the patient’s immune system before administering cellular therapies, reducing toxicity and side effects. For instance, in November 2024, Fate Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, launched FT522, an off-the-shelf CD19-targeted CAR NK cell therapy. This innovative therapy incorporates alloimmune defense receptor technology to enable the CAR NK cells to persist and selectively deplete pathogenic B cells in patients with relapsed or refractory B-cell lymphoma and autoimmune diseases, showing promising safety and efficacy results in early-phase clinical trials without the need for intense immune system suppression.

What Are Latest Mergers And Acquisitions In The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market?

In April 2023, NKGen Biotech, a US-based biopharmaceutical company, merged with Graf Acquisition Corp. IV to become a publicly listed company and advance its clinical development programs. With this acquisition, NKGen Biotech aims to secure funding and leverage the combined expertise and resources of both companies to accelerate innovation, expand its pipeline, and bring transformative therapies for neurodegenerative and autoimmune diseases to patients more efficiently. Graf Acquisition Corp. IV is a US-based publicly listed special purpose acquisition company (SPAC) focused on partnering with growth-stage companies in the life sciences sector.

What Defines the Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market?

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market includes revenues earned by entities through the research and development, clinical trial management, cell manufacturing, personalized treatment planning, and post-therapy patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Report 2026?

The chimeric antigen receptor-natural killer (car-nk) cell therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antigen receptor-natural killer (car-nk) cell therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.